Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
News|Articles|December 3, 2025
LabVantage Pharma LIMS: Ensuring Compliance, Speed & Quality in Pharmaceutical Manufacturing
Author(s)LabVantage
This piece of content details how LabVantage Pharma LIMS serves pharmaceutical manufacturers with built-in compliance, speed, and quality assurance. It describes a pre-validated, purpose-built platform that supports FDA 21 CFR Part 11, EudraLex Annex 11, and GxP standards. The system enables rapid deployment (go-live in ~90 days), automated workflows, instant Certificates of Analysis, and robust security. Labs can simplify operations, strengthen compliance, and accelerate batch release while safeguarding product quality.
Related to this article
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights
5